Peter Calverley
- Are the benefits of pulmonary rehabilitation sustained after 6 months?By Lily Zainudin, Paul Albert, Verity Ford and Peter CalverleyLily ZainudinRespiratory Medicine, University Hospital Aintree, Liverpool, United KingdomPaul AlbertRespiratory Medicine, University Hospital Aintree, Liverpool, United KingdomVerity FordRespiratory Medicine, University Hospital Aintree, Liverpool, United KingdomPeter CalverleyRespiratory Medicine, University Hospital Aintree, Liverpool, United Kingdom
- Efficacy of roflumilast in the frequent exacerbation COPD phenotypeBy Jadwiga Wedzicha, Klaus Rabe, Peter Calverley, Fernando Martinez, Dirk Bredenbröker, Manja Brose and Udo-Michael GoehringJadwiga Wedzicha1Academic Unit of Respiratory Medicine, UCL Medical School, London, United KingdomKlaus Rabe2Center for Pulmonology and Thoracic Surgery, Krankenhaus Grosshansdorf, Grosshansdorf, GermanyPeter Calverley3School of Clinical Sciences, University Hospital Aintree, Liverpool, United KingdomFernando Martinez4Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, United StatesDirk Bredenbröker5Department of Respiratory Medicine, Nycomed GmbH, Konstanz, GermanyManja Brose6Department of Data Science, Nycomed GmbH, Konstanz, GermanyUdo-Michael Goehring5Department of Respiratory Medicine, Nycomed GmbH, Konstanz, Germany
- The measurement of absolute lung volume without plethysmographyBy Ori Adam, Robert Shiner, Peter Calverley, Julian Solway, Robert Brown and Jeffrey FredbergOri Adam1Department of Geophysics and Planetary Sciences, Tel Aviv University, Tel Aviv, IsraelRobert Shiner2Department of Respiratory Medicine, Imperial College, London, United KingdomPeter Calverley3School of Medicine, University of Liverpool, Liverpool, United KingdomJulian Solway4Department of Medicine, University of Chicago, Chicago, IL, United StatesRobert Brown5Harvard Medical School, Harvard University, Boston, MA, United StatesJeffrey Fredberg6Harvard School of Public Health, Harvard University, Boston, MA, United States
- Changes in operating lung volume and symptoms during daily activity in COPDBy Daniela Savi, Sandy Jack, Paul Albert and Peter CalverleyDaniela Savi1Department of Clinical Medicine, Sapienza University of Rome, Rome, ItalySandy Jack2Department of Inflammation Research, Aintree University Hospital NHS Foundation Trust, Liverpool, Merseyside, United KingdomPaul Albert2Department of Inflammation Research, Aintree University Hospital NHS Foundation Trust, Liverpool, Merseyside, United KingdomPeter Calverley2Department of Inflammation Research, Aintree University Hospital NHS Foundation Trust, Liverpool, Merseyside, United Kingdom
- Reduced body mass index is associated with the presence of airflow obstruction in a rural Indian settingBy Biswajit Chakrabarti, Sabita Purkait, Punybrata Goon, Vicky Moore, Christopher Warburton, Peter Calverley, Justin Zaman and Rahul MukherjeeBiswajit Chakrabarti1Aintree Chest Centre, University Hospital Aintree, Liverpool, United KingdomSabita Purkait2Moitri Swasthya Kendra, Shramajibi Swasthya Udyog, Chengail, West Bengal, IndiaPunybrata Goon2Moitri Swasthya Kendra, Shramajibi Swasthya Udyog, Chengail, West Bengal, IndiaVicky Moore3Department of Respiratory Medicine & Physiology, Birmingham Heartlands Hospital, Birmingham, United KingdomChristopher Warburton1Aintree Chest Centre, University Hospital Aintree, Liverpool, United KingdomPeter Calverley5Clinical Sciences Centre, University Hospital Aintree, Liverpool, United KingdomJustin Zaman4Epidemiology & Public Health, Div of Population Health, University College London, United KingdomRahul Mukherjee3Department of Respiratory Medicine & Physiology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
- Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPDBy Peter Calverley, Fernando Martinez, Udo-Michael Goehring, Dirk Bredenbröker, Manja Brose and Claus VogelmeierPeter Calverley1School of Clinical Sciences, University Hospital Aintree, Liverpool, United KingdomFernando Martinez2Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, United StatesUdo-Michael Goehring3Department of Respiratory Medicine, Nycomed GmbH, Konstanz, GermanyDirk Bredenbröker3Department of Respiratory Medicine, Nycomed GmbH, Konstanz, GermanyManja Brose4Department of Data Science, Nycomed GmbH, Konstanz, GermanyClaus Vogelmeier5Department of Pneumology, University of Marburg, Marburg, Germany
- Efficacy of roflumilast in former and current smokers with COPDBy Peter Calverley, Udo-Michael Goehring, Fernando Martinez and Neil BarnesPeter Calverley1School of Clinical Sciences, University Hospital Aintree, Liverpool, United KingdomUdo-Michael Goehring2Department of Respiratory Medicine, Nycomed GmbH, Konstanz, GermanyFernando Martinez3Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, United StatesNeil Barnes4The London Chest Hospital, Barts & The London School of Medicine & Dentistry, London, United Kingdom
- Determination of COPD characteristics via unsupervised clustering of the ECLIPSE cohortBy Stephen Rennard, Bruno Delafont, Nicholas Locantore, Alvar Agusti, Peter Calverley, Edwin Silverman, Ruth Tal-Singer and Jorgen VestboStephen Rennard1University of Nebraska Medical Center, University of Nebraska, Omaha, NE, United StatesBruno Delafont2Department of Statistics, Boehringer-Ingelheim, Paris, FranceNicholas Locantore3Respiratory Medicines Development, GlaxoSmithKline, RTP, NC, United StatesAlvar Agusti4Institut del Torax, CIBER Enfermedades Respiratorias and Fundacion Caubet-Cimera, Barcelona, SpainPeter Calverley5Department of Respiratory Medicine, University of Liverpool, Liverpool, United KingdomEdwin Silverman6Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA, United StatesRuth Tal-Singer7Respiratory Center of Drug Development, GlaxoSmithKline, Philadelphia, PA, United StatesJorgen Vestbo8Cardiology and Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark
- Effect of roflumilast on hospitalizations in COPD patientsBy Eric Bateman, José Jardim, Udo-Michael Goehring, Manja Brose and Peter CalverleyEric Bateman1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaJosé Jardim1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaUdo-Michael Goehring1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaManja Brose1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaPeter Calverley1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- Risk of pneumonia related to budesonide use in COPD: An updated pooled analysisBy Don Sin, Donald Tashkin, Finn Radner, Ulf Sjobring, Anders Thoren, Peter Calverley and Stephen RennardDon Sin1Department of Medicine, University of British Columbia, Vancouver, CanadaDonald Tashkin2Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, Los Angeles, United StatesFinn Radner3Clinical Sciences, AstraZeneca R&D, Molndal, SwedenUlf Sjobring3Clinical Sciences, AstraZeneca R&D, Molndal, SwedenAnders Thoren3Clinical Sciences, AstraZeneca R&D, Molndal, SwedenPeter Calverley4School of Clinical Sciences, University of Liverpool, United KingdomStephen Rennard5Internal Medicine Section of Pulmonary and Critical Care, Nebraska Medical Center, Omaha, United States
- Differential dropout may affect exacerbation risk estimates differently in moderate-to-very severe COPDBy Peter Calverley, Göran Eriksson, Dirkje Postma, Christine Jenkins, Antonio Anzueto, Barry Make, Anders Persson, Malin Fagerås and Thomas SimilowskiPeter Calverley1Pulmonary and Rehabilitation Research Group, University Hospital Aintree, Liverpool, United KingdomGöran Eriksson2Research and Development, AstraZeneca, Lund, Sweden3Department of Respiratory Medicine and Allergology, University Hospital, Lund, SwedenDirkje Postma4Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, GRIAC Research Institute, University of Groningen, NetherlandsChristine Jenkins5Woolcock Institute of Medical Research, University of Sydney, Camperdown, AustraliaAntonio Anzueto6Department of Pulmonology, University of Texas Health Sciences Center, San Antonio, TX, United StatesBarry Make7Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO, United StatesAnders Persson8Research and Development, AstraZeneca, Mölndal, SwedenMalin Fagerås2Research and Development, AstraZeneca, Lund, SwedenThomas Similowski9Service de Pneumologie et Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
- The minimal clinically important difference (MCID) for the six minute walk (6MW) test in COPD in relation to deathBy Michael Polkey, Martijn Spruit, Lisa Edwards, Michael Watkins, Vincent Pinto-Plata, Jørgen Vestbo, Peter Calverley, Ruth Tal-Singer, Alvar Agusti, Per Bakke, Harvey Coxson, David Lomas, William MacNee, Stephen Rennard, Edwin Silverman, Bruce Miller, Courtney Crim, Julie Yates, Emiel Wouters and Bartholeme CelliMichael Polkey1Consultant Physician, Royal Brompton Hospital, London, United KingdomMartijn Spruit2Program Development Centre, CIRO+, a Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsLisa Edwards3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesMichael Watkins3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesVincent Pinto-Plata4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United StatesJørgen Vestbo5Respiratory Medicine, University of Manchester, United KingdomPeter Calverley6Department of Respiratory Medicine, School of Clinical Science, University of Liverpool, United KingdomRuth Tal-Singer7Galaxy Initiative, GlaxoSmithKline, King of Prussia, PA, United StatesAlvar Agusti8Institut del Tòrax, Hospital Clínic, IDIBAPS, CIBER Enfermedades Respiratorias and Fundación Caubet-Cimera, Barcelona, SpainPer Bakke9Institute of Medicine, University of Bergen, NorwayHarvey Coxson10Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, CanadaDavid Lomas11Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, United KingdomWilliam MacNee12ELEGI Colt Research Labs, University of Edinburgh/MRC Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, United KingdomStephen Rennard13Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, NE, United StatesEdwin Silverman14Channing Laboratory, Brigham & Women's Hospital, Boston, MA, United StatesBruce Miller7Galaxy Initiative, GlaxoSmithKline, King of Prussia, PA, United StatesCourtney Crim3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesJulie Yates3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesEmiel Wouters2Program Development Centre, CIRO+, a Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsBartholeme Celli4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
- ERICA (evaluating the role of inflammation in chronic airways disease): Extrapulmonary manifestations of COPDBy Divya Mohan, Carmel McEniery, Nicola Gale, Jonathan Fuld, Charlotte Bolton, William MacNee, Peter Calverley, Ruth Tal-Singer, Ian Wilkinson, Michael Polkey and John CockcroftDivya Mohan1NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, United KingdomCarmel McEniery2Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, United KingdomNicola Gale3Department of Cardiology, Wales Heart Research Institute, University Hospital Wales, Cardiff, United KingdomJonathan Fuld4Department of Respiratory Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United KingdomCharlotte Bolton5Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, United KingdomWilliam MacNee6MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United KingdomPeter Calverley7Department of Respiratory Medicine, University of Liverpool, Liverpool, United KingdomRuth Tal-Singer8Respiratory Therapy Area Unit, GlaxoSmithKline, King of Prussia, United StatesIan Wilkinson2Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, United KingdomMichael Polkey1NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, United KingdomJohn Cockcroft3Department of Cardiology, Wales Heart Research Institute, University Hospital Wales, Cardiff, United Kingdom
- One-year change in health status and outcomes in chronic obstructive pulmonary diseaseBy Sarah Wilke, Paul Jones, Hana Müllerova, Nicholas Locantore, Jorgen Vestbo, Ruth Tal-Singer, Frits Franssen, Alvar Agusti, Per Bakke, Peter Calverley, Harvey Coxson, Courtney Crim, Lisa Edwards, David Lomas, William MacNee, Stephan Rennard, Julie Yates, Emiel Wouters and Martijn SpruitSarah Wilke1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsPaul Jones2Division of Clinical Science, St. George’s University of London, London, United KingdomHana Müllerova3Respiratory Epidemiology, GlaxoSmithKline, Uxbridge, United KingdomNicholas Locantore4GlaxoSmithKline, Research Triangle Park, North Carolina,Jorgen Vestbo5Department of Respiratory Medicine, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark6Respiratory Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation, Manchester, United KingdomRuth Tal-Singer7GlaxoSmithKline, GlaxoSmithKline Research and Development, King of Prussia,Frits Franssen1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsAlvar Agusti8Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Barcelona, SpainPer Bakke9Department of Thoracic Medicine, Institute of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, NorwayPeter Calverley10Division of Infection and Immunity Clinical Sciences Centre, University Hospital Aintree, Liverpool, United KingdomHarvey Coxson11Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancover, CanadaCourtney Crim4GlaxoSmithKline, Research Triangle Park, North Carolina,Lisa Edwards4GlaxoSmithKline, Research Triangle Park, North Carolina,David Lomas12University of Cambridge, Cambridge Institute for Medical Research, Department of Medicine, Cambridge, United KingdomWilliam MacNee13MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United KingdomStephan Rennard14Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha,Julie Yates4GlaxoSmithKline, Research Triangle Park, North Carolina,Emiel Wouters1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands15Department of Respiratory Medicine, Maastricht University Medical Centre+, Maastricht, NetherlandsMartijn Spruit1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands
- The combination of low fat-free mass and high fat mass is related to functional outcome and systemic inflammation in patients with COPDBy Pavol Joppa, Frits Franssen, Ruzena Tkacova, Corrine Hanson, Stephen Rennard, Edwin Silverman, Merry-Lynn McDonald, Peter Calverley, Emiel Wouters and Erica RuttenPavol Joppa1Center of Expertise for Chronic Organ Failure, (Ciro+), Horn, Netherlands2Department of Respiratory Medicine, PJ Safarik University, Kosice, Slovakia (Slovak Republic)Frits Franssen1Center of Expertise for Chronic Organ Failure, (Ciro+), Horn, NetherlandsRuzena Tkacova2Department of Respiratory Medicine, PJ Safarik University, Kosice, Slovakia (Slovak Republic)Corrine Hanson3Medical Nutrition Education, School of Allied Health Professions University of Nebraska Medical Center, Omaha, NE,Stephen Rennard4Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE,Edwin Silverman5Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital / Harvard Medical School, Boston, MA,Merry-Lynn McDonald6Channing Division of Network Medicine, Brigham and Women´s Hospital / Harvard Medical School, Boston, MA,Peter Calverley7Pulmonary and Rehabilitation Medicine, University of Liverpool, Liverpool, United KingdomEmiel Wouters8Department of Respiratory Medicine, University of Maastricht, Maastricht, NetherlandsErica Rutten1Center of Expertise for Chronic Organ Failure, (Ciro+), Horn, Netherlands
- Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trialBy Ronald Dahl, Daniel Dusser, Robert Wise, Gordon Pledger, Antonio Anzueto, Achim Mueller, Andrew Fowler and Peter CalverleyRonald Dahl1Allergy Centre, Odense University Hospital, Odense, DenmarkDaniel Dusser2Service de Pneumologie, Hopital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceRobert Wise3Medicine - Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD,Gordon Pledger4Statistics, Independent Consultant, Hamilton, TX,Antonio Anzueto5Pulmonary/Critical Care, University of Texas and South Texas Health Care System, San Antonio, TX,Achim Mueller6Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyAndrew Fowler7Medical Affairs, Boehringer Ingelheim Ltd, Bracknell, United KingdomPeter Calverley8Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
- Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysisBy Mona Bafadhel, Lisa Davies, Peter Calverley, Shawn Aaaron, Christopher Brightling and Ian PavordMona Bafadhel1Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United KingdomLisa Davies2Aintree Chest Centre, University Hospital Aintree, Liverpool, United KingdomPeter Calverley2Aintree Chest Centre, University Hospital Aintree, Liverpool, United Kingdom3Institute of Ageing and Chronic Diseases, University of Liverpool, Liverpool, United KingdomShawn Aaaron4Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CanadaChristopher Brightling5Institute for Lung Health, NIHR Respiratory BioMedical Research Unit, University of Leicester, Leicester, United KingdomIan Pavord1Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM studyBy Henrik Watz, Peter Calverley, Pascal Chanez, Ronald Dahl, Marc Decramer, Bernd Disse, Helen Finnigan, Anne Kirsten, Roberto Rodriguez-Roisin, Kay Tetzlaff, Lesley Towse, Emiel Wouters and Helgo MagnussenHenrik Watz1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyPeter Calverley2Institute of Ageing and Chronic Disease, University Hospital Aintree, Liverpool, United KingdomPascal Chanez3Service de Pneumologie, Hôpital Nord, Marseille, FranceRonald Dahl4Allergy Centre, Odense University Hospital, Odense, DenmarkMarc Decramer5Department of Respiratory Diseases, University of Leuven, Leuven, BelgiumBernd Disse6Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyHelen Finnigan7Biometry and Data Management Department, Boehringer Ingelheim (UK), Berkshire, United KingdomAnne Kirsten1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyRoberto Rodriguez-Roisin8Servei de Pneumologia (ICT), Hospital Clínic-IDIBAPS-CIBERES, Barcelona, SpainKay Tetzlaff6Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany9Department of Sports Medicine, University of Tübingen, Tübingen, GermanyLesley Towse10Clinical Research Department, Boehringer Ingelheim (UK), Berkshire, United KingdomEmiel Wouters11Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, NetherlandsHelgo Magnussen1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany
- Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trialBy Peter Calverley, Daniel Dusser, Robert Wise, Gordon Pledger, Ronald Dahl, Achim Mueller, Jessica Montero Caballero and Antonio AnzuetoPeter Calverley1Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomDaniel Dusser2Service de Pneumologie, Hopital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceRobert Wise3Medicine - Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD,Gordon Pledger4Statistics, Independent Consultant, Houston, TX,Ronald Dahl5Allergy Centre, Odense University Hospital, Odense, DenmarkAchim Mueller6Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyJessica Montero Caballero7Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyAntonio Anzueto8Pulmonary/Critical Care, University of Texas and South Texas Health Care System, San Antonio, TX,
- Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg dosesBy Peter Calverley, Michael Könen-Bergmann, Norbert Metzdorf, Susan Bell and Jens HohlfeldPeter Calverley1Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomMichael Könen-Bergmann2Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, GermanyNorbert Metzdorf2Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, GermanySusan Bell3Statistics, Boehringer Ingelheim Pharma GmbH & Co KG, Bracknell, United KingdomJens Hohlfeld4Clinical Airway Research, Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Hannover, Germany
- The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM studyBy Helgo Magnussen, Pascal Chanez, Ronald Dahl, Marc Decramer, Bernd Disse, Helen Finnigan, Anne Kirsten, Roberto Rodriguez-Roisin, Kay Tetzlaff, Lesley Towse, Henrik Watz, Emiel Wouters and Peter CalverleyHelgo Magnussen1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyPascal Chanez2Service de Pneumologie, Hôpital Nord, Marseille, FranceRonald Dahl3Allergy Centre, Odense University Hospital, Odense, DenmarkMarc Decramer4Department of Respiratory Diseases, University of Leuven, Leuven, BelgiumBernd Disse5Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyHelen Finnigan6Biometry and Data Management Department, Boehringer Ingelheim (UK), Berkshire, United KingdomAnne Kirsten1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyRoberto Rodriguez-Roisin7Servei de Pneumologia (ICT), Hospital Clínic-IDIBAPS-CIBERES, Barcelona, SpainKay Tetzlaff5Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany8Department of Sports Medicine, University of Tübingen, Tübingen, GermanyLesley Towse9Clinical Research Department, Boehringer Ingelheim (UK), Berkshire, United KingdomHenrik Watz1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyEmiel Wouters10Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, NetherlandsPeter Calverley11Institute of Ageing and Chronic Disease, University Hospital Aintree, Liverpool, United Kingdom
- Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot studyBy Pasquale Pompilio, Valentina Isetta, Andrei Malinovschi, Jo Middlemass, Giulia Munaro, Mireia Dalmases, Christer Janson, Aloysius Niroshan Siriwardena, Roberta Macis, Paolo Zanaboni, Peter Calverley, Raffaele Dellaca and Roberto RossoPasquale Pompilio1R&D, Restech srl, Milano, Italy2TBMlab, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, ItalyValentina Isetta3Hospital Clinic - Facultat de Medicina, Universitat de Barcelona - CIBERES, Barcelona, SpainAndrei Malinovschi4Dept of Medical Sciences, Uppsala University, Uppsala, SwedenJo Middlemass5Community and Health Research Unit, University of Lincoln, Lincoln, United KingdomGiulia Munaro6Tesan spa, Vicenza, ItalyMireia Dalmases3Hospital Clinic - Facultat de Medicina, Universitat de Barcelona - CIBERES, Barcelona, SpainChrister Janson4Dept of Medical Sciences, Uppsala University, Uppsala, SwedenAloysius Niroshan Siriwardena5Community and Health Research Unit, University of Lincoln, Lincoln, United KingdomRoberta Macis2TBMlab, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, ItalyPaolo Zanaboni7Norwegian Centre for Integrated Care and TeleMedicine (NST), University Hospital of North Norway, Tromso, NorwayPeter Calverley8University of Liverpool, Liverpool, United KingdomRaffaele Dellaca1R&D, Restech srl, Milano, Italy2TBMlab, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, ItalyRoberto Rosso6Tesan spa, Vicenza, Italy
- Knowing when to stop: inhaled corticosteroids and COPDBy Peter CalverleyPeter CalverleyInstitute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
- LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levelsBy Peter Calverley, Christoph Hallmann, Norbert Metzdorf, Lars Grnke, Achim Mueller and David HalpinPeter Calverley1Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomChristoph Hallmann2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyNorbert Metzdorf2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyLars Grnke2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAchim Mueller2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyDavid Halpin3Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter, United Kingdom
- LATE-BREAKING ABSTRACT: Study to understand mortality and morbidIty in COPD (SUMMIT)By Jorgen Vestbo, Julie Anderson, Robert D. Brook, Peter Calverley, Bart Celli, Courtney Crim, Fernando Martinez, Julie Yates and David NewbyJorgen Vestbo1Centre for Respiratory Medicine and Allergy, The University of Manchester, Manchester, United KingdomJulie Anderson2Respiratory Statistics, GlaxoSmithKline, Uxbridge, Middlesex, United StatesRobert D. Brook3Division of Cardiovascular Medicine, Internal Medicine, University of Michigan, Ann Arbor, MI United StatesPeter Calverley4Respiratory Research Group, University Hospital Aintree, Liverpool, United KingdomBart Celli5Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA United StatesCourtney Crim6Respiratory Research and Development, GlaxoSmithKline, Research Triangle Park, NC United StatesFernando Martinez7Division of Pulmonary and Critical Care Medicine, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY United StatesJulie Yates6Respiratory Research and Development, GlaxoSmithKline, Research Triangle Park, NC United StatesDavid Newby8United States and British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
- Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trialBy Peter Calverley, Kay Tetzlaff, Achim Mueller, Norbert Metzdorf, Bernd Disse and Ronald DahlPeter Calverley1Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomKay Tetzlaff2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyAchim Mueller3Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH Co & KG, Biberach, GermanyNorbert Metzdorf2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyBernd Disse2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyRonald Dahl4Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
